Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares, rose in value on Thursday, July 10, with the stock price down by -5.31% to the previous day’s close as strong demand from buyers drove the stock to $0.23.
Actively observing the price movement in the last trading, the stock closed the session at $0.24, falling within a range of $0.2151 and $0.254. The value of beta (5-year monthly) was 1.372. Referring to stock’s 52-week performance, its high was $3.10, and the low was $0.15. On the whole, PCSA has fluctuated by -29.20% over the past month.
With the market capitalization of Processa Pharmaceuticals Inc currently standing at about $6.02 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PCSA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PCSA currently trading nearly -7.64% and -11.20% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.17, while the 7-day volatility ratio is showing 14.68% which for the 30-day chart, stands at 29.71%. Furthermore, Processa Pharmaceuticals Inc (PCSA)’s beta value is 1.30.
A comparison of Processa Pharmaceuticals Inc (PCSA) with its peers suggests the former has fared considerably weaker in the market. PCSA showed an intraday change of -5.31% in last session, and over the past year, it shrunk by -73.99%%.
Data on historical trading for Processa Pharmaceuticals Inc (NASDAQ:PCSA) indicates that the trading volumes over the past 10 days have averaged 12.55 and over the past 3 months, they’ve averaged 18.82 million. According to company’s latest data on outstanding shares, there are 26.19 million shares outstanding.
Nearly 13.24% of Processa Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 0.65% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.53 million shares as on 2025-06-13, resulting in a short ratio of 0.1. According to the data, the short interest in Processa Pharmaceuticals Inc (PCSA) stood at 466.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.7 million. The stock has fallen by -85.72% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PCSA stock heading into the next quarter.
